埃克替尼治疗晚期非小细胞肺癌疗效评估  

Ek for treatment of advanced non-small cell lung cancer curative effect evaluation

作　　者：孙红文[1] 周华[1] 赵培珠[1] 杨林珠[1] 雷常成[1] 熊国盛[1] 段晋[1] 

机构地区：[1]昆明医科大学第一附属医院,云南昆明650032

出　　处：《中华肿瘤防治杂志》2015年第B22期124-125,共2页Chinese Journal of Cancer Prevention and Treatment

摘　　要：目的探讨分子靶向药物埃克替尼治疗晚期非小细胞肺癌（non-smallcelllungcancer，NSCLC）的临床疗效。方法选取我院2013-01—2014-12收治的晚期NSCLC患者60例，所有患者采用分子靶向药物埃克替尼的治疗方法进行治疗，观察患者的治疗效果。结果患者的完全缓解3例（5．00％），部分缓解15例（25．00％），稳定28例（46．67％），出现进展14例（23．33％）。客观缓解率为30．00％，疾病控制率为76．67％，一年内的生存率为55．00％。腹泻反应11例（18．33％），为I～Ⅱ级；皮疹反应29例（48．33％）；转氨酶明显升高反应的有2例（3．33％），所有患者中都没有出现血液学毒性患者。结论晚期NSCLC患者采取分子靶向药物埃克替尼治疗的方法进行治疗，临床控制率相对较高，没有出现血液学毒性，药物治疗安全性相对较高，值得临床推广。OBJECTIVE To study the molecular targeted drugs for ek, the clinical curative effect of treatment of advanced non-small cell lung cancer. METHODS Selection of our hospital in the late 60 patients with non-small-cell lung cancer （NSCLC） from 2013-01 to 2014-12, all of the patients using molecular targeted drugs for ek treatment for treatment, the treatment effect were observed. RESULTS The patients with complete remission in 3 patients （5.00%） and partial in 15 cases （25.00%）, 28 cases （46.67%）, stable progress in 14 cases （23.33%）. Objective response rate was 30.00 %, the disease control rates is 76.67%, the survival rate of 55.00% a year. Reaction 11 cases （18.33%）, diarrhea is I - II level; Rash reaction 29 eases （48.33%） ; Aminotransferase significantly higher reaction in 2 cases （3.33%）, all of the patients did not appear in the patients with hematologic toxicity. CONCLUSION The patients with advanced nonsmall cell lung cancer treated with molecular targeted drugs for ek, the method of treatment, clinical control rates are rel- atively high, no hematology toxicity, medication safety is relative taller, worth clinical promotion.

关 键 词：分子靶向药物 埃克替尼 晚期非小细胞肺癌 治疗效果 

分 类 号：R734.2[医药卫生—肿瘤]